Cytovance Partners with Celltheon to Boost Biologics Manufacturing

• Cytovance Biologics partners with Celltheon to integrate cell line development and CDMO services.

• The collaboration aims to improve timelines, manufacturability, and product yield for complex biologics.

Cytovance Biologics and Celltheon have announced a partnership to meet the growing demand for complex biologics development and manufacturing in the US. This collaboration integrates Celltheon’s CHO-K1-based cell line development platform with Cytovance’s CDMO services.

Axel Schleyer, CCO of Cytovance, stated, “We have seen firsthand the improved timelines, manufacturability, and product yield that Celltheon’s expression technologies provide to their customers, and we are excited to now be able to welcome them and their novel therapeutics into our cGMP facilities.” This partnership aims to expand customer options for cell line development, enabling faster market entry.

Cytovance customers will gain access to Celltheon’s OmniCHO™ Platform for early-stage protein expression, CELLTHEON SMART™ Platform for stable clone development, pGL™ Vectors, and GOLDILOCKS™ transposase system. After upstream development, products can move to downstream development and cGMP manufacturing at Cytovance’s mammalian facilities, with bioreactor scale-up options of 1000L and 2000L.

Nikhil Goel, CTO of Celltheon, shared, “We are delighted to collaborate with the Cytovance team to further expand our partnerships and provide access to the CELLTHEON SMART™ Cell Line Development Platform, which serves as a critical starting point in the complex biologics manufacturing workflow.”